Didanosine (ddl, Videx)
Didanosine is available as buffered tablets, buffered or non-buffered powder, and non-buffered enteric-coated capsules (Videx EC).
Adverse effects
Treatment-limiting toxicities of didanosine have been dose-related peripheral neuropathy, pancreatitis and gastrointestinal disturbances. The risk of pancreatitis, neuropathy and lactic acidosis is enhanced when didanosine is combined with stavudine or tenofovir; the combination of didanosine and stavudine is no longer recommended for initial treatment or treatment of pregnant women. The combination of didanosine and zalcitabine is not recommended because of overlapping toxicities.